A coalition of more than 40 US lawmakers has formally urged the Trump administration to withdraw a proposed federal grant regulation, warning on 14 July that it would politicise scientific funding, erode American innovation and hand a strategic advantage to rivals, particularly China. The letter, addressed to Office of Management and Budget (OMB) Director Russell Vought, was led by California legislators including Senator Adam Schiff, Representative Zoe Lofgren, and Representative Salud Carbajal.

What the Proposed Rule Would Change

The regulation in question — formally titled the 'Regulation for Federal Financial Assistance' — would, according to the lawmakers, fundamentally restructure how federal research grants are awarded across every agency of the US government. Critics argue it would hand political appointees sweeping authority over the grant review process, displacing the peer-review system that has governed scientific funding for more than 75 years.

'The rule is unprecedented, expansive, and applies across the federal government to every agency that reviews grants and other financial assistance proposals. It would allow political appointees to control all aspects of the grant review process, setting the stage for politically motivated decision-making that places the whims of the President over the well-being of the American people,' the lawmakers wrote in their letter.

California's Stake — and the Broader Warning

California, consistently one of the largest recipients of federal research funding and home to globally ranked universities and technology companies, would be disproportionately affected, the signatories argued. They contended that merit-based, independent scientific review has underpinned American advances in medicine, engineering, national security, and technology for decades.

The letter cautioned that replacing peer review with political oversight could slow scientific progress across multiple sectors — from new medical treatments and environmental protection strategies to space exploration technologies. 'The proposed rule would weaken the scientific foundations of experimental research,' the lawmakers wrote, warning of cascading delays in fields ranging from cancer and Alzheimer's disease research to infectious disease and long-term clinical trials.

The China Competitiveness Concern

Lawmakers explicitly flagged the geopolitical dimension of the proposal, warning that China is actively increasing investments in scientific research while the proposed rule could allow political appointees without technical expertise to influence agencies such as NASA. They argued the regulation would damage the STEM talent pipeline and make it harder for universities, researchers, and businesses to attract international talent — further narrowing America's competitive edge.

This concern arrives at a moment when the US-China technology rivalry has intensified across semiconductors, artificial intelligence, and space exploration, making scientific research funding a matter of national security as much as academic policy.

Biomedical Research and Long-Term Impact

The letter raised particular alarm over biomedical research, warning that grants could be terminated on broad 'national interest' grounds, disrupting ongoing clinical trials and wasting prior federal investments. Lawmakers also expressed concern that universities could face restrictions on publication costs and permissible research topics — constraints they said would generate funding uncertainty that 'could reverberate for generations.'

'With such funding uncertainty and unpredictability, California and the rest of the country will backslide behind other nations in the areas of health, innovation, research, and scientific development. As such, we strongly urge you to rescind your proposed rule,' the letter concluded.

What Happens Next

The OMB has not publicly responded to the lawmakers' letter as of the time of reporting. Federal research funding has long anchored the US scientific ecosystem, supporting universities, national laboratories, and private-sector partnerships that have produced advances in medicine, aerospace, computing, and clean energy. Whether the administration proceeds with, amends, or withdraws the proposed regulation will have significant consequences for research institutions and technology companies nationwide.